Phase 2 Clinical Trial For IPF Patients With Chronic Cough

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

pf_phase 2

Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF).

Neurogenic disorders are conditions associated with the central nervous system and affect millions of individuals. They occur when certain nerves become hyper-sensitized due to distress, infection, inflammation or tissue injury; this sensitization can lead to chronic and debilitating symptoms.

Read more about it: